HUE028863T2 - mGlu 2/3 agonisták - Google Patents
mGlu 2/3 agonisták Download PDFInfo
- Publication number
- HUE028863T2 HUE028863T2 HUE13702872A HUE13702872A HUE028863T2 HU E028863 T2 HUE028863 T2 HU E028863T2 HU E13702872 A HUE13702872 A HU E13702872A HU E13702872 A HUE13702872 A HU E13702872A HU E028863 T2 HUE028863 T2 HU E028863T2
- Authority
- HU
- Hungary
- Prior art keywords
- hexane
- bicyclo
- mmol
- cyclopropane
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/26—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms containing rings other than aromatic rings
- C07C55/30—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms containing rings other than aromatic rings containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
- Szabadalmi igénypontok LI:(J) képlett* végsőiét, ahol R: hidrogénatom, R" hidrogénatom, és R'' hidrogénatom; IL hidrogénatom, R* t2.S>2^mirK)piopanoilcsoport. ë$ R:" hidrogénatom; IL hidmgénalom, IL (2éo-2~airdtK>4'mohRzulfmiii-d>utanolîcsopost, es R ' hidrogénatom; Rs hidïügéaatom, R2- 2-ammoaceulosoport, é$ hidrogénatom; RJ benzilcsoport, R" hidrogénatom, és R‘! botsai lesöpör?; vagy Rs <2*fiuotfenU)metüe$oporî, IL hidrogénatom, és R^é'-nutafeMlmpiksopiL tmgyiggy gyógyásaadlag elfogadhat! fája.
- 2, Az I, igénypont szerinti vegyidet, mely (/S,2SiÔ^dS)~2~am:mosptrofbtcikb[3.] ,0]osxlo··· 4,1 ^ciklcg'.;ro|>átt]-2,6-dtkarbortsáv, vagy egy gyógyászaülag elfogadható sója,
- 3, Az L igénypont szerinti vegyidet, mely (} S,2S<5R,6$)-2>aminospíro|;bicik!op, I .Öjhexái* 4, Î^-cIklûprdpânJ-2 J-dikarboásáL hidroklori!. 4, ,¾¾ L igénypont sleriiii vegyülöm mely ( /,1 2$.4&ό5ρ2-{\(2$}Φ atóiít^m^aui|]^Í^]spro(NcíkIo| 3 > 1.Ojhexân-fo1 '~cik\oprop«p!^~d|^^pfáVs vagy egy gyógyászán lag elfogadható sója, 5. A?: 1. igénypont szerinti vegyelek mely (i«S\2& ο ϊ·2~ iaminoproi^oiijamiaojspimfbicikiop. I .öjhexéB·^ l •-dk!opropân)-l»fe«di.krtï»sâ'v· hidroklorkl, ó Λ·ί 5 mem;v tt w i,n % egűdet,ne % t <óÓó óó/ <sm 3-0;~ó, amin<ípropanoü]ammo]spm4bidklo[3.1 .Ojhexán-4,1 '<ikiopropíuijP,ó-aikarbtmsav dítdáfoh
- 7, Az 1, igénypont szerinti vegyidet, mely (iβ,*$>i&óáNHU/SM" , "inepuvpd; οι ja' ,ηοΛ\ρ vptoik p ‘ü^vui ΑΓ e Alamo par 3 '‘-dikas bon»av* 1,4" diósán il: 0,5); hkkokíoríd. 8, Ä 1. igényponidszerinii vegyük*!, méh iiS, 2S, o b«tseeil]aminojspiro[biciklo[3.1,0jhexán-4, ! '<ik}opropén]-2>dikeis«¥, ^agy egk gyógyászatikg elfogadható sója,
- 9, Az !. Igénypont szerinti vegyüld, mely (/Ai.ye.k.öSpS-i^d^'-i-'amino-A-mpÖÄulisnti” buianoO)&mino;$pimfbteik!op, 1,0]hexan»4,1 '«ciklopropánj~2,6-4ikarbonsav hídrokiöfid, 10 \ó 1 igény pom .mernkt végvidék nach ;v/v7.1óK6S'>-5-1 p-amineaeetdbm^nvk^pirefbiemle^' - U,ho\an" brO'kloptep,m]*3,í>*dikaíb<.msav, vagy egy gyógyászatijai? elfogadható sója, 11 Λζ I si.eKY!VTi s/emr,, >, eg'- klek mely ( ' ΑΛΑ y IP- :aminoacetil}aabmV]spi.ro[bieiklol3,l33]hexárn4,r-cikíopmpánlP,ŐHÍlkarbpnsay bidroklorki,
- 12. Az. L igénypont szerinti vegyidet, .mely dilxwl! {ÍS,2SJR,6$y2- anunosp'rofok íkloj3,l.0jhexan'4J'-eiklept<'pa?ij~2,o-d'Aa'. exilai, vagy egy gyógy a.s/aülág e I fogadba tó sói a.
- 13, Az I. igénfpó# kegyUlek.mdy dihenzi! amioespirofbiéiklop. !,0jhazán-4,, 1 ’^kIopropàn]-2,6-dikM-boÂt; ly44ÉoxÉi§ MáseiÉU>.ri&> Mi Az l. igénypont szerinti vegyidet, mely bisz[(24ltmrféml}metill áüaiaospiro(bicikloP. I ,ú]ht*xán>4,1 ' 'CikJoprcfánjG.b'dikarboaiiat, vagy egy győgyászailág élfogadhiü sóiá,
- 15, Az I > igéóypnt szerinti \#gyüks|. i^í|á^^«ürfeúl}m^ü] U$J$SR&$}'2*·· arninospiro[biciklo|3,1 .0jhexát*4,l ^ikiopppásVJ^fedík^ÉmiléS MÉmkforid, l§. Gyógyászati készítmény, mely az MS. igénypontok bármelyike szerimi vegyükaei vagy sót és egy gyógyászatiéig elfogadható hordozót, higltószert vagy kötőanyagot tartalmaz,
- 17, Az Al á. igénypomok bármelyike szerinti vegyükt vagy só terápiában történi alkalmazás- m IS. Az t-l 5. igénypontok bármelyike szerinti vegyidet vagy só tartós f|rtafóm, nearopathlis fajdalom, Gonikna gyulladásos fájdukao, é? Mgeo tajdatom Mzu. kikerülő neurológiai betegség kezelésében történő alkalmazásra, !É:::A vegyükt vagy só a Î S, igényg» szerinti alküfmazásü% almi a nearolőglai betegség: tartós fajdalom, Ä. A végyilét vagy só a I S, igéa^óótiszeAnfi alkalmazásra, alól a mnttologmi betegség neampafáiás ftf dalom,
- 21, A vegyilet vagy só a Ü, tgépypppf: szedóti allaltnazásrá, éff a neurológiai betegség krónikus gyulladásos fajdalom.
- 22, A vegyület vagy só a If, ipnypoti szedni !ħi#| zsigeri: fájdalom.
- 23. Az MS. IpHyponleik bármelyike szerinti vegyilet vagy só skizofrénia, bipoláris betegség, állandósult íélelml állapot, és posttraMatlkus stressz kW! kikerülő pszichiátriai betegség kezelésében történő alkalmazásra.
- 24. A vegyÄt vagy sé a23i igénypont szerinti alkalmazásra, alto! a pszichiátriai betegség skizofrénia.
- 25. A vegyidet vagy só a 23. Igénypont szerint! alkalmazásra, aboi a pszichiátriai betegség bipoláris betegség;
- 26. A vegyidet vagy só alMgénypóni szednibetegség : állandósult íéleimi állapot.
- 27. A vegyület vagy só a 23. igénypont szerinti alká^, bÄgsig po során mánk us stressz.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12382038 | 2012-02-01 | ||
US201261619139P | 2012-04-02 | 2012-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE028863T2 true HUE028863T2 (hu) | 2017-01-30 |
Family
ID=48870759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE13702872A HUE028863T2 (hu) | 2012-02-01 | 2013-01-29 | mGlu 2/3 agonisták |
Country Status (35)
Country | Link |
---|---|
US (1) | US8575214B2 (hu) |
EP (1) | EP2809647B1 (hu) |
JP (1) | JP5755821B2 (hu) |
KR (1) | KR101518365B1 (hu) |
CN (1) | CN104093703B (hu) |
AP (1) | AP2014007821A0 (hu) |
AR (1) | AR089718A1 (hu) |
AU (1) | AU2013215396B2 (hu) |
BR (1) | BR112014018760A8 (hu) |
CA (1) | CA2863085C (hu) |
CL (1) | CL2014001928A1 (hu) |
CO (1) | CO7020921A2 (hu) |
CR (1) | CR20140344A (hu) |
DK (1) | DK2809647T3 (hu) |
DO (1) | DOP2014000179A (hu) |
EA (1) | EA023678B1 (hu) |
ES (1) | ES2592166T3 (hu) |
GT (1) | GT201400168A (hu) |
HK (1) | HK1199014A1 (hu) |
HR (1) | HRP20160867T1 (hu) |
HU (1) | HUE028863T2 (hu) |
IL (1) | IL233732A0 (hu) |
LT (1) | LT2809647T (hu) |
MA (1) | MA35884B1 (hu) |
MX (1) | MX355779B (hu) |
NZ (1) | NZ626456A (hu) |
PE (1) | PE20141680A1 (hu) |
PH (1) | PH12014501725A1 (hu) |
PL (1) | PL2809647T3 (hu) |
PT (1) | PT2809647T (hu) |
RS (1) | RS54976B1 (hu) |
SG (1) | SG11201404138VA (hu) |
SI (1) | SI2809647T1 (hu) |
TW (1) | TW201343610A (hu) |
WO (1) | WO2013116174A1 (hu) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101481164B1 (ko) * | 2008-01-30 | 2015-01-09 | 주식회사 미래셀바이오 | 체세포 유래 다능성 줄기세포의 제조 방법 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
NZ323205A (en) | 1995-11-16 | 1999-06-29 | Lilly Co Eli | Excitatory amino acid derivatives |
ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
WO2000012464A1 (fr) * | 1998-08-31 | 2000-03-09 | Taisho Pharmaceutical Co., Ltd. | Derives de 6-fluorobicyclo[3. 1.0]hexane |
GB2355982A (en) * | 1999-11-03 | 2001-05-09 | Lilly Co Eli | Heterocyclic amino acids |
CA2411059A1 (en) * | 2000-06-28 | 2002-12-06 | Taisho Pharmaceutical Co., Ltd. | Novel dicarboxylic acid derivatives |
US7256217B2 (en) | 2001-01-11 | 2007-08-14 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
EP1351925A1 (en) | 2001-01-11 | 2003-10-15 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
EA014979B1 (ru) * | 2002-06-11 | 2011-04-29 | Эли Лилли Энд Компани | Пролекарства возбуждающих аминокислот |
AU2004252017B2 (en) | 2003-06-26 | 2009-10-08 | Taisho Pharmaceutical Co., Ltd. | 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative |
AR079343A1 (es) * | 2009-12-21 | 2012-01-18 | Lilly Co Eli | Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico |
-
2013
- 2013-01-14 AR ARP130100108A patent/AR089718A1/es unknown
- 2013-01-18 TW TW102102088A patent/TW201343610A/zh unknown
- 2013-01-29 JP JP2014555613A patent/JP5755821B2/ja not_active Expired - Fee Related
- 2013-01-29 NZ NZ626456A patent/NZ626456A/en not_active IP Right Cessation
- 2013-01-29 BR BR112014018760A patent/BR112014018760A8/pt active Search and Examination
- 2013-01-29 RS RS20160611A patent/RS54976B1/sr unknown
- 2013-01-29 MX MX2014008598A patent/MX355779B/es active IP Right Grant
- 2013-01-29 AU AU2013215396A patent/AU2013215396B2/en not_active Ceased
- 2013-01-29 CN CN201380007664.4A patent/CN104093703B/zh not_active Expired - Fee Related
- 2013-01-29 PT PT137028726T patent/PT2809647T/pt unknown
- 2013-01-29 EP EP13702872.6A patent/EP2809647B1/en active Active
- 2013-01-29 AP AP2014007821A patent/AP2014007821A0/xx unknown
- 2013-01-29 CA CA2863085A patent/CA2863085C/en not_active Expired - Fee Related
- 2013-01-29 SI SI201330238A patent/SI2809647T1/sl unknown
- 2013-01-29 DK DK13702872.6T patent/DK2809647T3/en active
- 2013-01-29 US US13/752,432 patent/US8575214B2/en active Active
- 2013-01-29 WO PCT/US2013/023529 patent/WO2013116174A1/en active Application Filing
- 2013-01-29 HU HUE13702872A patent/HUE028863T2/hu unknown
- 2013-01-29 EA EA201491291A patent/EA023678B1/ru not_active IP Right Cessation
- 2013-01-29 PL PL13702872T patent/PL2809647T3/pl unknown
- 2013-01-29 SG SG11201404138VA patent/SG11201404138VA/en unknown
- 2013-01-29 ES ES13702872.6T patent/ES2592166T3/es active Active
- 2013-01-29 LT LTEP13702872.6T patent/LT2809647T/lt unknown
- 2013-01-29 PE PE2014001210A patent/PE20141680A1/es not_active Application Discontinuation
- 2013-01-29 KR KR1020147021318A patent/KR101518365B1/ko active IP Right Grant
-
2014
- 2014-07-17 CR CR20140344A patent/CR20140344A/es unknown
- 2014-07-21 IL IL233732A patent/IL233732A0/en not_active IP Right Cessation
- 2014-07-22 CL CL2014001928A patent/CL2014001928A1/es unknown
- 2014-07-24 MA MA37242A patent/MA35884B1/fr unknown
- 2014-07-29 GT GT201400168A patent/GT201400168A/es unknown
- 2014-07-31 CO CO14167101A patent/CO7020921A2/es unknown
- 2014-07-31 PH PH12014501725A patent/PH12014501725A1/en unknown
- 2014-07-31 DO DO2014000179A patent/DOP2014000179A/es unknown
- 2014-12-11 HK HK14112463.7A patent/HK1199014A1/xx unknown
-
2016
- 2016-07-13 HR HRP20160867TT patent/HRP20160867T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2784667C (en) | Mglu2 agonists | |
TW201742863A (zh) | 靶向蛋白質之嵌合化合物、組合物、方法及其用途 | |
AU2018204692A1 (en) | Glutaminase inhibitors and methods of use | |
DK2809647T3 (en) | MGlu 2/3 agonists | |
EP3790885B1 (en) | 1-imidazothiadiazolo-2h-pyrrol-5-one derivatives | |
CA2836485C (en) | Bicyclo (3.1.0) hexane- 2,6 -dicarboxylic acid derivatives as mglu2 receptor agonist | |
BR112017004868B1 (pt) | Derivados de pirrolopirimidina como antagonistas do receptor nmda nr2b e composição farmacêutica que os compreende |